Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2023-06-07 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. It reports clinical trial data updates and a milestone payment related to a collaboration agreement. The document is relatively short (2998 characters) and primarily serves as an announcement of recent developments rather than a full financial or management report. It does not contain detailed financial statements or comprehensive analysis. The Form 6-K is typically used for current reports by foreign issuers and often fits under general regulatory announcements. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-06-07 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. Form 6-K is used for submitting current reports of foreign private issuers, often including press releases or other material information. The document includes a joint press release as an exhibit and is dated June 5, 2023. The text does not contain detailed financial statements or substantive financial data, but rather serves as a regulatory filing to report material information. Given the short length (1451 characters) and the nature of the content, this is a Regulatory Filing (RNS) rather than a full report or announcement of a report publication.
2023-06-05 English
6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Mereo BioPharma Group plc. It reports the results of the 2023 Annual General Meeting (AGM) held on May 22, 2023, including detailed voting outcomes on various resolutions such as approval of the annual report and accounts for the year ended December 31, 2022, re-appointment of auditors, directors' remuneration report, and re-election of directors. The document primarily focuses on the submission of matters to a vote of security holders and the official voting results. It does not contain the full annual report or financial statements but rather the voting results related to the AGM. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6858 characters) and content confirm it is not merely an announcement of a report publication but a detailed voting result report.
2023-05-22 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, reporting that it has regained compliance with the Nasdaq minimum bid price requirement. The content is an announcement of a regulatory compliance status update and includes a press release as an exhibit. The document is relatively short (3133 characters) and does not contain detailed financial statements or substantive financial data. It is primarily a regulatory announcement about listing compliance rather than a full financial report or earnings release. According to the rules, such regulatory announcements that do not contain full financial data or detailed reports should be classified as Regulatory Filings (RNS).
2023-05-08 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo Biopharma Group plc, with the SEC. It announces the transfer of the company's American Depositary Shares listing from the Nasdaq Global Market to the Nasdaq Capital Market. The document includes details about the transfer approval, compliance with listing requirements, and a press release attached as an exhibit. The document length is 4104 characters, which is relatively short and primarily serves as an announcement rather than a full report. It does not contain financial statements or detailed financial analysis. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a Delisting Announcement (DLST) since the shares remain listed, nor is it a Capital/Financing Update (CAP) or other categories related to financial results or management changes. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a listing transfer and does not fit more specific categories.
2023-05-05 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. It provides first quarter 2023 financial information including cash balances and net cash burn, but it is not a full quarterly report with detailed financial statements or substantive financial data. The document is relatively short (5184 characters) and serves as a periodic update rather than a comprehensive interim or annual report. It also includes forward-looking statements and a signature by the CFO. Form 6-K filings typically serve as regulatory filings to provide updates and information to the SEC and investors but do not constitute full financial reports like 10-K or 10-Q. Therefore, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement and update rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2023-04-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.